CollPlant Biotechnologies
CLGN
16 hedge funds and large institutions have $1.93M invested in CollPlant Biotechnologies in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0.11% less ownership
Funds ownership: 1.19% → 1.08% (-0.11%)
16% less funds holding
Funds holding: 19 → 16 (-3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
53% less capital invested
Capital invested by funds: $4.08M → $1.93M (-$2.15M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Pinnacle Associates
New York
|
+$102K |
| 2 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$38K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$29.4K |
| 4 |
VF
Virtu Financial
New York
|
+$24.2K |
| 5 |
LWMI
Legacy Wealth Management (Idaho)
Boise,
Idaho
|
+$7.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$51.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$16.4K |
| 3 |
Renaissance Technologies
New York
|
-$8.8K |
| 4 |
Morgan Stanley
New York
|
-$4.93K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
CLGN Hedge Fund Activity: Q4 2025 in Review
16 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2025, worth a combined $1.93M — down 53% from $4.08M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLGN and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Pinnacle Associates, adding an estimated $102K. The largest seller was Heights Capital Management, exiting entirely with an estimated $51.8K sold.
- 16 institutional investors held CollPlant Biotechnologies (CLGN) as of Q4 2025, down from 19 in Q3 2025.
- Funds reported $1.93M of CollPlant Biotechnologies stock for Q4 2025, down 53% quarter-over-quarter.
- 3 funds opened new CollPlant Biotechnologies positions in Q4 2025 and 5 closed out, a net change of -2 holders.
- The largest CollPlant Biotechnologies buyer in Q4 2025 was Pinnacle Associates, an estimated $102K added.
- The largest CollPlant Biotechnologies seller in Q4 2025 was Heights Capital Management, an estimated $51.8K sold.
Based on aggregated 13F filings for Q4 2025.